Health for Life Capital II has achieved its first close thanks to commitments from strategic partners Danone, Novartis, Lesaffre, Wright Medical, Unicéréales and Bel.

GV participated as a new investor, as Harvard's genetic medicine developer Beam Therapeutics completed a round that followed $87m in series A funding last year.

ETH’s Paul Scherrer Institute has launched Araris Biotech to deliver production technology for site-specific ADCs that enable them to be used without being engineered from each patient.

Satt Sud-Est spinouts Click4Tag, C4Hydro and C4Biocontrol will merge to boost the commercialisation of microbe monitoring technologies built on research from six institutions.

University of Tokyo’s Utec has extended its foray into Indian VC investments by starting an accelerator in partnership with local venture fund Blume Ventures.

GV participated as a new investor, as genetic medicine developer Beam Therapeutics completed a round that followed $87m in series A funding last year.

The rechargeable hearing aid producer has now raised more than $144m altogether, having collected about $52m in a series D round featuring Nan Fung Life Sciences.

Blue Cross of Idaho was among the investors in a series B round that took the healthcare analytics platform operator's overall funding to more than $26m

Roche Venture Fund has taken part in a $38.7m round that will fund sales and commercialisation of MacuLogix's AMD diagnostics system.

Oxford-founded biopharmaceutical development instrument manufacturer Refeyn has secured funding from the university and OSI to help scale manufacturing and distribution.